S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:PRDS

Pardes Biosciences (PRDS) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$2.16
$2.16
50-Day Range
$2.13
$2.16
52-Week Range
$0.75
$3.93
Volume
400 shs
Average Volume
359,530 shs
Market Capitalization
$133.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.00
PRDS stock logo

About Pardes Biosciences Stock (NASDAQ:PRDS)

Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to treat and prevent viral diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California. As of August 31, 2023, Pardes Biosciences, Inc. operates as a subsidiary of MediPacific, Inc.

PRDS Stock News Headlines

Pardes Biosciences Announces Closing of Tender Offer
This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
Pardes Biosciences Seeking Strategic Alternatives
Pardes Biosciences (PRDS) Receives a Hold from SVB Securities
Pardes Biosciences Inc.
SVB Securities downgrades Pardes Biosciences (PRDS) to a Hold
See More Headlines
Receive PRDS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pardes Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:PRDS
Fax
N/A
Employees
57
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.00
High Stock Price Target
$2.00
Low Stock Price Target
$2.00
Potential Upside/Downside
-7.4%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
4 Analysts

Profitability

Net Income
$-96,630,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.51 per share

Miscellaneous

Free Float
36,711,000
Market Cap
$133.95 million
Optionable
Not Optionable
Beta
0.42
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Thomas G. Wiggans (Age 71)
    CEO & Chairman
    Comp: $859.4k
  • Dr. Uri A. Lopatin M.D. (Age 51)
    Founder & Director
    Comp: $786.96k
  • Ms. Heidi Henson CPA (Age 57)
    Chief Financial Officer
    Comp: $564.6k
  • Ms. Elizabeth Haber Lacy J.D. (Age 56)
    Gen. Counsel & Corp. Sec.

PRDS Stock Analysis - Frequently Asked Questions

Should I buy or sell Pardes Biosciences stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pardes Biosciences in the last twelve months. There are currently 4 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PRDS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PRDS, but not buy additional shares or sell existing shares.
View PRDS analyst ratings
or view top-rated stocks.

What is Pardes Biosciences' stock price target for 2024?

4 equities research analysts have issued 1-year price targets for Pardes Biosciences' shares. Their PRDS share price targets range from $2.00 to $2.00. On average, they anticipate the company's share price to reach $2.00 in the next year. This suggests that the stock has a possible downside of 7.4%.
View analysts price targets for PRDS
or view top-rated stocks among Wall Street analysts.

This page (NASDAQ:PRDS) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners